SG11202104499RA - Pharmaceutical formulations for subcutaneous administration - Google Patents

Pharmaceutical formulations for subcutaneous administration

Info

Publication number
SG11202104499RA
SG11202104499RA SG11202104499RA SG11202104499RA SG11202104499RA SG 11202104499R A SG11202104499R A SG 11202104499RA SG 11202104499R A SG11202104499R A SG 11202104499RA SG 11202104499R A SG11202104499R A SG 11202104499RA SG 11202104499R A SG11202104499R A SG 11202104499RA
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulations
subcutaneous administration
subcutaneous
administration
formulations
Prior art date
Application number
SG11202104499RA
Inventor
Ehab Moussa
Matthew Rosebraugh
Feroz Jameel
Nancy Sever
Maurizio F Facheris
Weining Z Robieson
Charles S Locke
Sven Stodtmann
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11202104499RA publication Critical patent/SG11202104499RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202104499RA 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration SG11202104499RA (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862767546P 2018-11-15 2018-11-15
US201962843945P 2019-05-06 2019-05-06
US201962863093P 2019-06-18 2019-06-18
US201962863113P 2019-06-18 2019-06-18
US201962863101P 2019-06-18 2019-06-18
US201962898214P 2019-09-10 2019-09-10
PCT/US2019/061626 WO2020102628A1 (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Publications (1)

Publication Number Publication Date
SG11202104499RA true SG11202104499RA (en) 2021-05-28

Family

ID=68835352

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104499RA SG11202104499RA (en) 2018-11-15 2019-11-15 Pharmaceutical formulations for subcutaneous administration

Country Status (14)

Country Link
US (1) US20200155578A1 (en)
EP (1) EP3880210A1 (en)
JP (1) JP2022507528A (en)
KR (1) KR20210091139A (en)
CN (1) CN113015531A (en)
AU (1) AU2019379806A1 (en)
BR (1) BR112021009353A2 (en)
CA (1) CA3117983A1 (en)
IL (1) IL282842A (en)
MX (1) MX2021005776A (en)
SG (1) SG11202104499RA (en)
TW (1) TW202031265A (en)
UY (1) UY38473A (en)
WO (1) WO2020102628A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022352845A1 (en) 2021-10-27 2024-04-11 Abbvie Inc. Subcutaneously administered foslevodopa/foscarbidopa treatments for advanced parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
PT3209302T (en) * 2014-10-21 2019-07-19 Abbvie Inc Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
EP3487843A1 (en) 2016-07-22 2019-05-29 Syngenta Participations AG Microbiocidal oxadiazole derivatives
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
BR112021009353A2 (en) 2021-11-23
IL282842A (en) 2021-06-30
MX2021005776A (en) 2021-07-02
KR20210091139A (en) 2021-07-21
UY38473A (en) 2020-06-30
CN113015531A (en) 2021-06-22
TW202031265A (en) 2020-09-01
CA3117983A1 (en) 2020-05-22
US20200155578A1 (en) 2020-05-21
WO2020102628A1 (en) 2020-05-22
EP3880210A1 (en) 2021-09-22
JP2022507528A (en) 2022-01-18
AU2019379806A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL258464A (en) Pharmaceutical formulations for the oral delivery of peptide drugs
IL283134A (en) Alcohol-resistant drug formulations
GB201807942D0 (en) Pharmaceutical formulation
CA187580S (en) Administration set for infusion pump
HUP1700253A1 (en) Solid preparations for oral administration
ZA202006570B (en) Pharmaceutical formulations
IL279127A (en) Delivery devices for administering drugs
ZA202102871B (en) Pharmaceutical formulation
HK1248544A1 (en) Stable pharmaceutical composition for oral administration
IL285674A (en) Pharmaceutical formulations
SG11202010124SA (en) Stable pharmaceutical formulation
IL278927A (en) Pharmaceutical formulation
GB201807040D0 (en) Drug delivery
IL290894A (en) Pharmaceutical formulation
EP3773730A4 (en) Drug delivery formulations
HK1245646A1 (en) Pharmaceutical composition for oral administration
IL280184A (en) Drug delivery devices
IL280118A (en) Medicinal preparation for external use
IL282842A (en) Pharmaceutical formulations for subcutaneous administration
IL291283A (en) Drug delivery formulations
ZA202006346B (en) Pharmaceutical preparation
SG11202101547WA (en) Pharmaceutical composition for oral administration
SG11202010792TA (en) Improved pharmaceutical formulations
EP3925647A4 (en) Drug solution administration device
GB201906473D0 (en) Pharmaceutical formulation